TITLE:
Chordoma Sociodemographic, Clinical and Therapeutic Aspects in National Institute of Oncology Rabat Morocco: A Report of 9 Cases
AUTHORS:
Gaël Kietga, Patricia Agbanglanon, Bertrand Compaore, Evrard Seka, Amine Lachgar, Noureddine Benjaafar
KEYWORDS:
Chordoma, Diagnosis, Radiation Therapy, Morocco
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.12 No.1,
January
20,
2021
ABSTRACT: Introduction: Chordoma is a rare bone tumor, which develops mainly from the sacrum, the
base of the skull, or the spine. Surgery + radiotherapy (if necessary) is the
standard treatment. Data on chordoma are scarce in this region, and thus, here we summarized 9 patients with
this tumor whom we treated in this institute. Material: Nine
chordoma patients were summarized, who were treated in National Institute of
Oncology in Rabat between 2013 and 2018. We
retrieved data from medical charts and analyzed the clinical characteristics
of this tumor. Results: The average age was 49 years (range: 29 - 72), with male: female of 3:6. The
manifestation-diagnosis time was 4 months (range: 2 - 14). Regarding the
tumor location, lumbosacral spine; 5, the skull; 4. Mass was evident in 6. Signs
of locoregional compressions (paraparesis or tetraparesis) were observed in 3.
As for treatment, a partial tumor excision was performed in 8, with 3 patients
undergoing a wide excision. Radiotherapy was done; 3 patients with a dose of 46
Gy, 3 patients with 66 Gy, 1 patient with 50 Gy, and 1 patient with a 16 Gy
gamma radio-knife in a single session. 4 patients with a dose of 46 Gy, 2
patients with 60 Gy, and 1 patient with a 16 Gy gamma radio-knife in a single
session. Of 9, 4 patients had good locoregional control whereas 5 patients had
local recurrence. Conclusion: Chordoma is a predominantly local
aggressive tumor with low metastatic potential. The surgical excision remains
the main prognostic factor. Advances in radiotherapy may improve local control.
These data are of use in management of this tumor in Rabat (Morocco).